Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,076 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC.
Kanemura H, Hayashi H, Tomida S, Tanizaki J, Suzuki S, Kawanaka Y, Tsuya A, Fukuda Y, Kaneda H, Kudo K, Takahama T, Imai R, Haratani K, Chiba Y, Otani T, Ito A, Sakai K, Nishio K, Nakagawa K. Kanemura H, et al. Among authors: suzuki s. JTO Clin Res Rep. 2022 Jul 1;3(8):100373. doi: 10.1016/j.jtocrr.2022.100373. eCollection 2022 Aug. JTO Clin Res Rep. 2022. PMID: 35941997 Free PMC article.
A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing.
Sakai K, Takeda M, Shimizu S, Takahama T, Yoshida T, Watanabe S, Iwasa T, Yonesaka K, Suzuki S, Hayashi H, Kawakami H, Nonagase Y, Tanaka K, Tsurutani J, Saigoh K, Ito A, Mitsudomi T, Nakagawa K, Nishio K. Sakai K, et al. Among authors: suzuki s. Sci Rep. 2019 Aug 5;9(1):11340. doi: 10.1038/s41598-019-47673-9. Sci Rep. 2019. PMID: 31383922 Free PMC article.
Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Yonesaka K, Iwama E, Hayashi H, Suzuki S, Kato R, Watanabe S, Takahama T, Tanizaki J, Tanaka K, Takeda M, Sakai K, Azuma K, Chiba Y, Atagi S, Nishio K, Okamoto I, Nakagawa K. Yonesaka K, et al. Among authors: suzuki s. Sci Rep. 2019 Dec 20;9(1):19501. doi: 10.1038/s41598-019-55939-5. Sci Rep. 2019. PMID: 31862929 Free PMC article.
Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study.
Kurosaki T, Mitani S, Tanaka K, Suzuki S, Kanemura H, Haratani K, Fumita S, Iwasa T, Hayashi H, Yoshida T, Ishikawa K, Kitano M, Otsuki N, Nishimura Y, Doi K, Nakagawa K. Kurosaki T, et al. Among authors: suzuki s. Anticancer Drugs. 2021 Jan 1;32(1):95-101. doi: 10.1097/CAD.0000000000001006. Anticancer Drugs. 2021. PMID: 32976215 Free PMC article. Clinical Trial.
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M, Takahama T, Sakai K, Shimizu S, Watanabe S, Kawakami H, Tanaka K, Sato C, Hayashi H, Nonagase Y, Yonesaka K, Takegawa N, Okuno T, Yoshida T, Fumita S, Suzuki S, Haratani K, Saigoh K, Ito A, Mitsudomi T, Handa H, Fukuoka K, Nakagawa K, Nishio K. Takeda M, et al. Among authors: suzuki s. Oncologist. 2021 Apr;26(4):e588-e596. doi: 10.1002/onco.13639. Epub 2021 Jan 6. Oncologist. 2021. PMID: 33325566 Free PMC article.
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
Suzuki S, Haratani K, Hayashi H, Chiba Y, Tanizaki J, Kato R, Mitani S, Kawanaka Y, Kurosaki T, Hasegawa Y, Okabe T, Tanaka K, Akashi Y, Ozaki T, Nishio K, Ito A, Nakagawa K. Suzuki S, et al. Eur J Cancer. 2022 Jan;161:44-54. doi: 10.1016/j.ejca.2021.11.011. Epub 2021 Dec 15. Eur J Cancer. 2022. PMID: 34922263
14,076 results
You have reached the last available page of results. Please see the User Guide for more information.